StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) stock

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.17−0.71 (-2.64%)

Close on Nov 18, 2026Market cap $3.34BP/E –Yield –

Viking Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Viking Therapeutics's price to book ratio was 8.1× on Nov 11, 2026, against 5.8× a year earlier. Over the last 5 years it ranged from 0.9× to 23.6×, with a median of 5.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.1×+2.6
2025Dec 31, 20255.5×+0.6
2024Dec 31, 20244.9×−0.1
2023Dec 29, 20235.1×+0.3
2022Dec 30, 20224.8×+3.1
2021Dec 31, 20211.7×+0.1
2020Dec 31, 20201.6×−0.4
2019Dec 31, 20192.0×+0.2
2018Dec 31, 20181.8×−50.2
2017Dec 29, 201752.0×+49.7
2016Dec 30, 20162.3×−0.2
2015Dec 31, 20152.5×–

More Viking Therapeutics figures

See a number that looks wrong?